Clinical Trial Update: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating AK104 as first-line therapy for locally advanced unresectable or metastatic gastric adenocarcinoma and gastroesophageal junction aden…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Akeso | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: COMPLETED